Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.

Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C.

J Clin Psychiatry. 2006 Apr;67(4):547-53.

PMID:
16669719
2.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
3.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
4.

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker S, Hoffmann VP, Conley R, Durell T.

BMC Psychiatry. 2010 Nov 3;10:89. doi: 10.1186/1471-244X-10-89.

5.

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17-25. doi: 10.3371/CSRP.5.1.3.

PMID:
21459735
6.

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

Chen CK, Chen YC, Huang YS.

Psychiatry Clin Neurosci. 2009 Feb;63(1):17-22. doi: 10.1111/j.1440-1819.2008.01886.x. Epub 2008 Dec 1.

8.

Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program.

Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M.

J Clin Psychiatry. 2004 Apr;65(4):471-7.

PMID:
15119908
9.

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.

Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG.

J Clin Psychopharmacol. 2006 Apr;26(2):157-62.

PMID:
16633144
10.

Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.

Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R.

J Clin Psychiatry. 2005 Feb;66(2):205-12.

PMID:
15705006
11.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

12.

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC.

Am J Psychiatry. 2005 May;162(5):954-62.

PMID:
15863798
14.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
15.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
16.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
17.

Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.

Cordes J, Thünker J, Regenbrecht G, Zielasek J, Correll CU, Schmidt-Kraepelin C, Lange-Asschenfeldt C, Agelink MW, Kahl KG, Gaebel W, Klimke A, Hauner H.

World J Biol Psychiatry. 2014 Apr;15(3):229-41. doi: 10.3109/15622975.2011.592546. Epub 2011 Jul 11.

PMID:
21745127
18.
19.

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.

Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L.

J Clin Psychopharmacol. 2008 Aug;28(4):392-400. doi: 10.1097/JCP.0b013e31817e63a5.

PMID:
18626265
20.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Conley RR, Mahmoud R.

Am J Psychiatry. 2001 May;158(5):765-74. Erratum in: Am J Psychiatry 2001 Oct;158(10):1759.

PMID:
11329400

Supplemental Content

Support Center